Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer Indicated in Patients With Prostate Cancer
May 30, 2024 03:00 ET
|
Curium
first doses of PYLCLARI in France for prostate cancer patients
Curium annonce les premieres doses commerciales en France de PYLCLARI® - un traceur PET innovant 18F-PSMA indique dans le cancer de la prostate
May 30, 2024 03:00 ET
|
Curium US LLC
PARIS, 30 mai 2024 (GLOBE NEWSWIRE) -- Curium, leader mondial de la médecine nucléaire, annonce aujourd'hui que suite à la Publication au Journal Officiel du 2 mai, , les patients français ont reçu...
Curium Extends Irradiation Partnership With NRG I PALLAS in Netherlands for Continuous Supply of Lutetium-177 to Treat 1,000s of Cancer Patients Each Year
May 29, 2024 03:32 ET
|
Curium
PARIS, May 29, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that it has signed a long-term agreement to extend its current partnership with NRG I PALLAS for...
Curium: Erste Kommerzielle Dosen von PYLCLARI® in Deutschland Verfügbar - Ein Innovativer 18f-PSMA PET Tracer für Patienten Mit Prostatakrebs
May 06, 2024 04:25 ET
|
Curium
PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Curium, ein weltweit führendes Unternehmen der Nuklearmedizin, gab heute bekannt, dass in München und Nürnberg die ersten kommerziellen Dosen von PYLCLARI®...
Curium Announces First Commercial Doses in Germany of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
May 06, 2024 04:25 ET
|
Curium
Curium announced that today in Munich and Nurnberg, Germany the first commercial doses of PYLCLARI® have been delivered.
Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials
April 23, 2024 00:01 ET
|
Curium
patient enrollment in clinical trial
Curium Announces First Commercial Dose in the Netherlands of PYLCLARI® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
April 09, 2024 08:50 ET
|
Curium
Curium proudly introduces the first commercial dose of PYLCLARI® in the Netherlands, revolutionizing prostate cancer diagnosis. This innovative 18F-PSMA PE
キュリウム (Curium)、エチャシバシ･モンロール (Eczacibaşi-Monrol) の買収に合意し、ルテチウム177の生産能力とPETのフットプリントを大幅に拡大する計画
April 09, 2024 04:13 ET
|
Curium US LLC
提案されているエチャシバシ･モンロールの買収により、次のようなことが達成される: ...
Curium Berencana untuk Secara Signifikan Meningkatkan Kapasitas Lutetium-177 dan Jejak PET Melalui Perjanjian untuk Mengakuisisi Eczacibaşi-Monrol
April 09, 2024 04:13 ET
|
Curium US LLC
Akuisisi Eczacıbaşı-Monrol yang diusulkan akan: Meningkatkan kemitraan yang sudah ada untuk Lu-177 yang membentuk produsen isotop terkemukaMenambahkan 12 situs PET ke jaringan Curium yang sudah...
Curium 计划通过收购 Eczacibaşi-Monrol 的协议大幅扩大镥-177 产能及 PET 业务范围
April 09, 2024 04:13 ET
|
Curium US LLC
此项拟议的 Eczacıbaşı-Monrol 收购将： 在现有的镥-177 合作伙伴关系基础上，创立领先的同位素制造商在 Curium 目前没有业务的地区为其现有网络增加 12 个 PET 站点为 Curium 增加 SPECT 生产能力和广泛的物流基础设施提高诊断和治疗方案的可靠性，从而造福患者 巴黎, April 09, 2024 (GLOBE NEWSWIRE) --...